Balzhan Shaizadayevna Myrzakhmetova

Dr. Balzhan Shaizadayevna Myrzakhmetova


Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
12 March 2020 in Animals
Verified
Journal Article
Open access
PDF file
AIArman Issimov
Arman Issimov
LKLespek Kutumbetov
Lespek Kutumbetov
MOMukhit B. Orynbayev
Mukhit B. Orynbayev
BKBerik Khairullin
Berik Khairullin
BMBalzhan Shaizadayevna Myrzakhmetova
Balzhan Shaizadayevna Myrzakhmetova
PWPeter White
Peter White
Samples collected for PCR from recipient animals tested positive in 5 out of 6 cases, while the virus was isolated from 4 of 6 animals. The clinical signs exhibited by recipient animals were mostly moderate in nature with only one severe case. To our knowledge, this is the first time that transmission of LSDV by three Stomoxys species has been demonstrated, and their role as mechanical vectors of LSDV is indicated.

12 August 2022 in Human Vaccines & Immunotherapeutics
Verified
Journal Article
Open access
ANAinur Nurpeisova
Ainur Nurpeisova
BKBerik Khairullin
Berik Khairullin
RARuslan Abitayev
Ruslan Abitayev
KSKamshat Shorayeva
Kamshat Shorayeva
KJKuanysh Jekebekov
Kuanysh Jekebekov
KZKunsulu Zakarya
Kunsulu Zakarya
This article describes the results of a preclinical safety and immunogenicity study of QazCovid-in®, the first COVID-19 vaccine developed in Kazakhstan, on BALB/c mice, rats, ferrets, Syrian hamsters and rhesus macaques (Macaca mulatta). The study’s safety data suggests that this immunobiological preparation can be technically considered a Class 5 nontoxic vaccine. The series of injections that were made did not produce any adverse effect or any change in the general condition of the model animals’ health, while macroscopy and histology studies identified no changes in the internal organs of the BALB/c mice and rats. This study has demonstrated that a double immunization enhances the growth of antibody titers as assessed by the microneutralization assay (MNA) and the enzyme-linked immunosorbent assay (ELISA) in a pre-clinical immunogenicity test on animal models. The best GMT results were assessed in MNA and ELISA 7 days after re-vaccination; however, we noted that GMT antibody results in ELISA were lower than in MNA. A comparative GMT assessment after the first immunization and the re-immunization identified significant differences between model animal groups and a growth of GMT antibodies in all of them; also, differences between the gender groups were statistically significant. Moreover, the most marked MNA immune response to the QazCovid-in® vaccine was seen in the Syrian hamsters, while their SARS-CoV-2-specific antibody activity as assessed with ELISA was the lowest.

12 December 2024 in Vaccines
Verified
Journal Article
Open access
PDF file
LKLespek Kutumbetov
Lespek Kutumbetov
BMBalzhan Shaizadayevna Myrzakhmetova
Balzhan Shaizadayevna Myrzakhmetova
ATAiganym Tussipova
Aiganym Tussipova
GZGulzhan Zhapparova
Gulzhan Zhapparova
ТТТалшын Муратовна Тленчиева
Талшын Муратовна Тленчиева
AKAslan Kerimbayev
Aslan Kerimbayev
The research conducted in this preclinical study assesses QazCovid-live, a live attenuated COVID-19 vaccine created in Kazakhstan, by conducting preclinical evaluations of safety, immunogenicity, and allergenicity in various animal models, including mice, rats, hamsters, and guinea pigs. The vaccine, developed by attenuating SARS-CoV-2 via numerous Vero cell passages, had no significant adverse effects in acute and subacute toxicity assessments, even at elevated dosages. Allergenicity testing indicated the absence of both immediate and delayed hypersensitivity reactions. Immunogenicity evaluations revealed strong virus-neutralizing antibody responses, especially following intranasal and intratracheal delivery. Studies on reversibility and transmission further validated the vaccine’s stability and non-pathogenicity. The data indicate that QazCovid-live is safe, immunogenic, and prepared for clinical trials, presenting a potential strategy for COVID-19 prevention.

5 July 2024 in Problems of Virology
Verified
Journal Article
Open access
PDF file
BMBalzhan Shaizadayevna Myrzakhmetova
Balzhan Shaizadayevna Myrzakhmetova
GZGulzhan Zhapparova
Gulzhan Zhapparova
KBKarina Bisenbayeva
Karina Bisenbayeva
ATA S Toytanova
A S Toytanova
MTM S Tuyskanova
M S Tuyskanova
LKLespek Kutumbetov
Lespek Kutumbetov
Introduction. Specific prevention of a number of infectious diseases has been introduced into the vaccination schedule. The production of immunoprophylactic drugs, in order to establish standard properties, including safety and specific effectiveness, requires strict adherence to manufacturing regulations, and the reliability of the results obtained requires monitoring of these parameters. The specific effectiveness of vaccine preparations is standardized according to the indicators of stimulation of specific antibody response formed in the body of vaccinated model biological objects. Objective. Determination of the immune reactivity of white mice to vaccination with the QazVac vaccine to establish the possibility of using them as a biological model in assessing the immunogenicity of the vaccine instead of Syrian hamsters. Materials and methods. The immune reactivity of model animals was assessed by the seroconversion rate, dynamics of antibody titers to the SARS-CoV-2 virus formed in the body after vaccination with the test vaccine. In the case of seropositivity of animals before administration of vaccine or placebo, the level of immune reactivity was calculated by the difference in antibody titers between control and vaccinated animals or by the difference in antibody titers before and after immunization. Specific antibodies were detected and their titer was determined using a neutralization reaction. Results. The research results showed that the tested biological models had approximately the same immune reactivity to the administration of the QazVac vaccine, confirmed by the level and dynamics of antibody titers. When analyzing the fold increase in antibody titers in comparison to those of control animals, Syrian hamsters were more reactive compared to mice. But SPF white mice were standardized in their lack of the immune reactivity to SARS-CoV-2 virus before the immunization. Conclusion. The data obtained indicate that the immune reactivity of white mice to the administration of the QazVac vaccine in terms of the rate and dynamics of the formation of virus-neutralizing antibodies is approximately equivalent to the immune reactivity of Syrian hamsters. Before immunization with the vaccine, SPF white mice, in contrast to Syrian hamsters, do not have humoral immunity specific to the SARS-CoV-2 virus. The immune reactivity equivalent to that observed of Syrian hamsters and the absence of antibodies to the SARS-CoV-2 virus at a baseline indicate the superiority of the use of white mice in assessing the immunogenicity of vaccines against COVID-19 and/or obtaining specific factors of humoral immunity.

26 December 2023 in Problems of Virology
Verified
Journal Article
Open access
PDF file
MTMoldir S. Tuyskanova
Moldir S. Tuyskanova
Kuandyk ZhugunissovKuandyk Zhugunissov
Kuandyk Zhugunissov
MÖMehmet ÖZASLAN
Mehmet ÖZASLAN
BMBalzhan Shaizadayevna Myrzakhmetova
Balzhan Shaizadayevna Myrzakhmetova
LKLespek Kutumbetov
Lespek Kutumbetov
Introduction. At the beginning of December 2019, humanity has faced a new problem caused by coronavirus. In Hubei province of central China, epidemic events associated with severe primary viral pneumonia in humans began to develop. The isolated etiological agent was identified as a representative of Coronaviridae family. The global pandemic associated with the new coronavirus infection, acute respiratory syndrome type 2 (Severe acute respiratory syndrome 2, SARS-CoV-2), has become a challenge for humanity. Objective. In our work, we assessed the replicative ability and pathogenesis of the SARS-CoV-2 virus in hamsters. Materials and methods. Syrian hamsters (n=16) randomly divided into two groups were used in experiment. The first group was infected intranasally with the SARS-CoV-2 virus, strain SARS-CoV-2/human/KAZ/KZ_Almaty/2020 deposited in GenBank under number MZ379258.1. The second group remained as a control group. Clinical manifestations of the disease in hamsters were observed within 14 days. Samples were collected on days 3, 5, 7, 9, 12, and 14 postinfection. The obtained samples were tested for viral isolation in cell culture, histological examination and analysis of viral RNA by RT-PCR. Results. SARS-CoV-2 virus isolates showed efficient replication in the lungs of hamsters, causing pathological lung lesions in animals infected intranasally. Clinical manifestations of the disease in hamsters infected with this virus were characterized by a decrease in temperature and body weight, wetness and ruffled fur, and frequent stroking of the nasal planum. High virus titers were observed following the virus isolation in cell cultures from nasal, oral swabs and lungs of animals infected intranasally. Pathological autopsy demonstrated pathological changes in the lungs. Moreover, transmission by airborne droplets has been established when a healthy hamster was kept together with animals infected using the intranasal method. Conclusion. In conclusion, our study showed that the Syrian hamster model is a useful tool for studying the SARS-CoV-2 pathogenesis, as well as testing vaccine candidates against acute respiratory syndrome type 2.

25 January 2023 in Biosafety and Biotechnology
Verified
Journal Article
Open access
PDF file
BMBalzhan Shaizadayevna Myrzakhmetova
Balzhan Shaizadayevna Myrzakhmetova
KBKarina Bisenbayeva
Karina Bisenbayeva
MKM. Sh. Kaukarbayeva
M. Sh. Kaukarbayeva
YBYe. D. Burashev
Ye. D. Burashev
LKL. B. Kutumbetov
L. B. Kutumbetov
в настоящей работе представлены данные по изучению культуральных свойств генетического варианта Омикрон вируса SARS-CoV-2 коронавирусной инфекции COVID-19. Наиболее пермессивными биологическими системами для репродукции данного варианта вируса являются культуры клеток Vero, РК-15, СПЭВ, МА-104, MARC-145. Оптимальными условиями культивирования генетического варианта Омикрон вируса SARS-CoV-2 в изучаемых клеточных линиях оказались следующие параметры: посевная концентрация клеток 200 тыс/см3, множественность заражения – 0,01 ТЦД50/кл, срок культивирования вируса – 2 сут, площадь поражения клеточного монослоя перед сбором вируса – 75-80%, биологическая активность вируса в пределах от 4,14±0,31 до 6,66±0,22 lg ТЦД50/см3.